QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

• QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies
• CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making
• Launch marks QIAGEN’s expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing

HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17–21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside additional technologies supporting laboratory workflows, clinical decision-making and the development of Laboratory Developed Tests (LDTs).

The QIAstat-Dx BCID GPF Plus AMR Panel enables laboratories to identify 20 gram-positive bacterial and fungal pathogen targets (GPF) and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies. This launch expands the QIAstat-Dx portfolio beyond respiratory, gastrointestinal and meningitis / encephalitis testing into bloodstream infection applications.

In bloodstream infections, timely identification of pathogens and resistance markers is critical, as treatment decisions often need to be made quickly. By delivering results in about one hour, the QIAstat-Dx BCID GPF Plus AMR Panel is designed to support laboratory workflows while providing clinically relevant information for patient management, antimicrobial stewardship and infection control efforts.

“Rapid identification of pathogens and resistance markers is important in bloodstream infections, where treatment decisions often need to be made quickly,” said Nadia Aelbrecht, Vice President, Head of Infectious Diseases at QIAGEN. “With this launch, we are extending the QIAstat-Dx portfolio into bloodstream infection testing and giving laboratories a new option to generate clinically relevant results from positive blood cultures and colonies. We plan to further expand this offering with additional panels in development, including those targeting gram-negative pathogens.”

QIAstat-Dx integrates sample preparation, molecular testing and data analysis into a single workflow. The systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.

For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/applications/syndromic-testing.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.

Contacts

QIAGEN contacts:

Public Relations

e-mail: [email protected]

Investor Relations

e-mail: [email protected]